A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating the combination of a study drug, venetoclax, and a standard
chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome.
The drugs involved in this study are:
- Venetoclax
- R-EPOCH:
- Rituximab
- Etoposide
- Prednisone
- Vincristine Sulfate (Oncovin)
- Cyclophosphamide
- Doxorubicin Hydrochloride (Hydroxydaunomycin)
- R-CHOP:
- Rituximab
- Cyclophosphamide Vincristine
- Doxorubicin Hydrochloride (Hydroxydaunomycin)
- Sulfate (Oncovin)
- Prednisone